H oney has been recognised to be a good wound care agent, possessing both antimicrobial and healing properties.
1,2 The spectrum of antibacterial activity is broad (with 37 genera of bacteria shown to be susceptible), [3] [4] [5] and a range of medical honeys exist on the market (for example, chestnut, manuka, thyme, Revamil, manufactured by Bfactory Health Products, Multifloral and Medihoney).
6 Their mechanism of action is thought to be multifactorial; due to the honey preparation itself (in terms of physical properties including pH and hyperosmolarity), and the innate antibacterial components of honey (methylglyoxal, bee defensin-1, and hydrogen peroxide (H 2 O 2 ). 6 To date, antibacterial resistance to honey has not been detected. 7, 8 Despite a 5000-year history as a topical antiseptic, a major limitation of natural honeys is that the honey may not be of a predictable and consistent quality, since the production depends on a large number of factors (for example, the floral source, the species of bee, geographical location, harvesting process, and subsequent storage conditions). 6 This has implications for large-scale production. There are also variation between the formulations of medicalgrade honeys, although these are generally standardised in preparation.
Surgihoney RO (SH1) is a licensed sterile product based on natural organic honey from a variety of sources. It has been developed for wound care and as a prophylactic dressing agent for wounds. It has been engineered (through a proprietary engineering process) so that it produces consistently high levels of antibacterial activity through reactive oxygen species (ROS).
9 ROS causes oxidative damage due to the production of hydroxyl radicals, leading to restricted bacterial growth and DNA degradation. 10, 11 Further prototype formulations exist, in addition to SH1, which have enhanced production of H 2 O 2 . This means, theoretically, that antibacterial activity can be set at a higher potency if required.
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In vitro studies by Dryden et al. 13 ,14 have shown research Clinical outcomes have also been favourable with SH1. In a pilot study looking at the prevention of surgical site infection (SSI) in patients undergoing caesarean section (CS) surgery, 12 SH1 was offered to all patients who had undergone a CS. Recipients were then monitored over 30 days for the development of infection, and rates of infection were compared with a previous cohort of patients who received no SH1. It reduced SSI by 60% compared with normal wound dressings, and was found to offer considerable cost savings over other preparations.
T H I S A RT I C L E I S R E P R I N T E D F RO M T H E J O U R N A L O F WO U N D C A R E
12 Further favourable outcomes were observed when SH1 was used to reduce bacterial colonisation in long lines in oncology patients.
14 Although these in vitro and clinical studies provide good evidence to support the antimicrobial activity of SH1, no work has yet been performed to assess the activity of this engineered honey against biofilms. Biofilms are associated with wound chronicity, and are present in 60% of those with chronic wound infections.
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This in vitro study was undertaken to assess whether SH1 has any antibacterial activity against biofilms, in terms of ability to prevent their formation. To evaluate this, SH1 was tested on a range of biofilm-producing bacteria and the activity compared against two standard medical-grade honeys and commercially available honey-and silver-containing antimicrobial wound dressings.
Methods
In vitro experiments were conducted on a panel of important wound pathogens (Table 1) to determine the antibacterial effects of Surgihoney RO (Matoke Holdings, UK), Medihoney (Derma Sciences, UK) and Activon tube 100% medical grade Manuka honey (Advancis Medical, UK), these will be referred to as SH1, Med and MH, respectively.
There were five antimicrobial dressings (AMDs) tested alongside SH1 on a limited panel of the isolates, so that any observed effects of SH1 could be compared with commercially available dressings containing honey, or alternative antimicrobial agents. The selection of honey-containing AMDs reflects those available in the formulary at our hospital, a major tertiary referral centre.
A total of 16 organisms (previously identified as good biofilm-producers) 16 were tested against the three honey formulations ( Aquacel Ag+ extra (Silver) Convatec Ionic silver impregnated hydrofibre pad composed of a combination of silver and 'anti-biofilming agents'
The ionic silver in the dressing kills pathogenic microorganisms, both planktonic and within bacterial biofilms, including wound bacteria, yeasts and moulds. The dressing also disrupts and absorbs biofilm, prevents biofilm formation/ reformation and increases the efficiency of silver transfer to microorganisms.
31,32
Actilite ( Hydrogel sheet (1mm thick) attached to a semi-polyurethane membrane by a thin fibrous bonding layer. The hydrogel contains 30% medical-grade honey.
As above.
The panel contained a mixture of well-characterised control strains (PS_PA01, PS_6749, ACI_C59, ACI_C60, ACI_19606, EC_042, The isolates were all varied in terms of antibiogram (data not shown), stored at −80°C on Protect beads, and were cultured on cysteine lactose electrolyte deficient (CLED) agar, or blood agar (as appropriate; Biomerieux, France) before each experiment. Honeys and AMDs (Table 2) were freshly opened and within date when used. Experiments were performed using at least two biological replicates, and at least six technical replicates of each isolate per test dilution. 
Preparation of the honey
The honeys were prepared in the same way and tested at a range of dilutions from 1:3 down to 1:6144. The strongest concentration (1:3) was made by placing 6ml of honey into a universal tube and adding 14ml of water to make a total volume of 20ml, which was then serially double diluted down in sterile autoclaved distilled water until 1:6144 was reached. Dilution from the neat product was necessary since the viscosity of the neat honey meant that it was impossible to standardise the volume used in the experiments at this concentration. The dilution chosen (1:3) was the most concentrated solution that could be accurately pipetted into the test wells.
Impact of the honey on biofilm formation
The ability of the honey formulations to prevent biofilm formation was assessed using a crystal violet (CV) biofilm formation assay 18 with the endpoint measurement being the 'minimum biofilm inhibitory concentration' (MBIC).
Overnight cultures of the test strains (grown in 5ml of Lysogeny broth (LB; Oxoid)) were diluted in fresh antibiotic-free Muller-Hinton broth (Oxoid) to an optical density at 600nm (OD600) of 0.1, and then 100μl seeded into wells of a 96-well microtiter tray (MTT) (Fisher Scientific), alongside 100μl of either diluted honey (with water as diluent) or sterile distilled water. The honeys were tested at the following dilutions: 1:3, 1:6, 1:12, 1:24, 1:48, 1:96, 1:192, 1:384, 1:768, 1:1536, 1:3072, and 1:6144. Suitable controls were included in each assay, comprising 100μl overnight bacterial culture with 100μl water (for the positive control), or 200μl Muller-Hinton broth alone (for the negative control). This composition of the positive control was selected so that both the positive control and the test wells contained the same volume and concentration of bacteria, and the same amount of broth. Two biological and three technical replicates were performed for each strain and each honey dilution, respectively.
Plates were sealed and statically incubated at 33°C; the temperature of the surface of a wound.
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After 72 hours, the liquid was removed from the wells and the plates rinsed in tap water to remove any unbound cells. Any existing biofilms were then visualised through staining with 200μl of 1% CV (Sigma Aldrich, Poole, UK), further rinsed (as above) to remove unbound CV, and dye solubilised by the addition of 200μl of 70% ethanol. The OD600 of the solubilised CV solution was then measured using a FLUOstar Optima (BMG Labtech) to assess the biomass of the biofilms.
If positive and negative controls for each test plate were within a normal range, the rest of the data were analysed for statistical significance by comparing values at each dilution of honey with untreated (positive) controls using the students' t-test. The MBIC was defined as the lowest dilution of honey where there was both statistical significance in the t-test (p value <0.05) and a prevention of biofilm biomass accumulation ≥50% compared with the positive control.
Preparation of antimicrobial dressings
The following AMD were prepared for testing: Aquacel Ag, Aquacel Ag+ extra (both Convatec), Actilite (Advancis Medical), L-Mesitran Net, and L-Mesitran Hydro (both from L-Mesitran Wound Care). These dressings were chosen as they either i) represent the most commonly used silver dressings in our burns unit (Aquacel Ag, and Aquacel Ag + extra), or ii) are composed of honey (Actilite, L-Mesitran Net, and L-Mesitran Hydro).
Each sterile dressing was carefully cut into a number of 1cm 2 pieces (sufficient for one piece per test well) using a sterile scalpel or a pair of flame -sterilised scissors. Details of these dressings (and references to published work) are in Table 2 .
Impact of antimicrobial dressings on biofilm formation
Overnight cultures of the test strains (grown in 5ml LB) were diluted in fresh antibiotic-free Muller-Hinton broth to an optical density at 600nm of 0.1, and then 1ml was seeded into wells of a 24-well MTT (Corning, New York), with 1ml of either diluted honey (from 1:3 to 1:1536) or sterile water. For the AMD test wells, one piece of dressing was placed into the well containing the 2ml bacterial suspension and water.
The plates were processed and analysed using the above methods. No MBIC values were possible for AMD, so the change in biofilm biomass (compared with positive control) was calculated.
Results
All 16 bacterial isolates were tested against all three honeys, and a subset of four were additionally tested against the AMDs, achieving at least two but up to six technical replicates per dilution. The number of replicates can be seen in Tables 3 and 4 , respectively.
The mean average optical densities of the solubilised CV were plotted per species and for all honeys and/or AMD to visually represent any prevention in the accumulation of biofilm biomass achieved by the treatment at the range of dilutions. Sample data are shown in Fig 1 ( showing the difference in the abilities of the three honeys to prevent biofilm formation of PS_1586), Fig 2 showing the similarities in the abilities of the three honeys to prevent biofilm formation of EC_042 and Fig 3 showing the performance of the AMD compared with SH1 for a range of Pseudomonas aeruginosa isolates.
The MBIC for the honeys was determined and is reported in Table 3 . All honeys demonstrated antibacterial activity against the formation of biofilms. The (Table 4) .
Impact of the honeys on biofilm formation
SH1 was able to prevent biofilm formation for all 16 of the isolates, with MBIC values ranging from 1:6 (PS_PA01 and PS_1586) to 1:192 (MDR_C, and MRSA_ F483) ( Table 3 ). MH was able to prevent biofilm formation of 14 of the 16 isolates, but was ineffective for two isolates (PS_PA01 and MRSA_F475). Here, there was no statistically significant prevention of biomass accumulation even when the strongest dilution of honey was used (1:3). This finding was repeatable.
Of the 14 isolates, MH was effective at preventing biofilms for eight (PS_1054, PS_6749, ACI_AYE, MDR_C, EC_042, MSSA_10788, MRSA_F483, and MSSA_F77) when used at the same dilution as SH1 (denoted by * Table 3 ), but required a stronger dilution than SH1 for the remaining six isolates (PS_1586, Table 3 ). In summary, six of the isolates (PS_1586, ACI_ C59, ACI_C60, ACI_19606, MDR_B and MDR_D) have MBICs of ≤1:6, three of 1:12 (PS_1054, PS_6749 and ACI_AYE), with the remainder of the MBICs ranging from 1:24 to 1:192 (Table 3 ). There did not appear to be a trend or pattern between susceptibility and pathogen group in the data.
Med performed similarly to MH, and was able to prevent biofilm formation for 15 of the 16 isolates, when used at equivalent (6/15 isolates), stronger (seven isolates), and also weaker (two isolates) dilutions compared with SH1 (denoted by *, † , ‡ Table 3 ).
Med was ineffective against biofilm production by one isolate (PS_PA01), where there was no statistically significant reduction in biofilm biomass, even when the strongest dilution of honey was used (1:3). With Med, five of the isolates had an MBIC of ≤1:6 (all Acinetobacter baumannii isolates, and MDR_D), which is similar to MH where five of the isolates also have MBICS of ≤1:6. The highest MBIC observed with Med was with PS_6749, where the lowest effective concentration to inhibit biofilm formation was 1: 1536. This was statistically significant (p=0.009) and there was a greater than 50% reduction in biofilm biomass compared with the positive control (data not shown). 
Comparison of the honeys
Although all the honeys were antibacterial and able to prevent the formation of biofilms for the majority of the isolates tested, SH1 was generally the most potent. SH1 was effective at lower dilutions than both the other honeys for five of the isolates (ACI_C59, ACI_C60, ACI_19606, MDR_B, and MDR_D), and was equivalently effective to the other honeys for a further six isolates (PS_1054, MDR_C, EC_042, MSSA_10788, MRSA_F483, and MSSA_F77). For the remaining five isolates, SH1 was either the only effective honey (PS_PA01), was one of two effective honeys (MRSA_F475), or gave concordant/discordant results compared with MH and Med (PS_1586, PS_6749, ACI_AYE).
Generally, MH and Med have similar MBIC for all isolates. However, for ACI_AYE, MH was superior to Med, and could prevent biofilm formation at 1:12 (the same effective dilution as SH1), compared with 1:3 for Med. There was also a difference in MBIC between MH (MBIC of 1:6) and Med (MBIC of 1:24) for MDR_B. All these results are statistically significant (p≤0.05).
On two occasions (PS_1586 and PS_6749), Med demonstrated superior potency to the other honeys. For the latter, the MBIC was 1:1536 (p=0.009), compared with 1:12 for both SH1 and MH (Fig 4) . This may be explained by the enhanced growth at 1:24 observed with SH1 and MH for this isolate.
Comparison of the antibacterial activity of engineered honey and the antimicrobial dressings
The activity of SH1 was additionally tested and compared with a range of AMDs. This honey was chosen owing to the higher potency observed early on in the experiments, as it was not logistically possible to test all honeys in this experiment.
Pseudomonas aeruginosa isolates, PS_PA01, PS_6749, PS_1054, and PS_1586 were tested against SH1 and the range of AMD, achieving at least two, and up to six replicates per isolate (Table 4 ). The % change in biofilm biomass with each dressing or SH1 dilution was calculated based on the untreated positive control and are listed alongside those that were statistically significant (p<0.05; Table 4 These data show that there is a large variation in the ability of the test agents to prevent the formation of biofilms of the Pseudomonas isolates tested. SH1 was effective at preventing biofilm formation of all isolates when used at a dilution of 1:3 with reductions in accumulations ranging from 79% (with PS_1586) to 94.1% (with PS_PA01). All of these reductions are statistically significant (p<0.05). In fact, SH1 still resulted in reduced biofilm formation (that was statistically significant) when used down to 1:6 (where there was an 82% reduction for Generally, the Gram-negative organisms were most susceptible to the honeys, including those MDR organisms. SH1 was the most potent of all the honeys, being effective at lower concentrations (weaker dilutions) than those required for MH and Med, and compared favourably against the two commonly used silver dressings. SH1 was also more effective at preventing biofilm formation in vitro of four Pseudomonas aeruginosa isolates than the three commercially available honey-containing dressings. While we did not conduct an extensive evaluation against all available honey-containing AMDs, we have compared all those available in our hospital that contain honey of some variety.
Honeys (including those of medical grade) are diverse, and it is known that potency can vary as much as 100-fold.
22 Cooke et al. 9 showed that the antibacterial activity of SH1 was due to the generation of H 2 O 2 and reactive oxygen species (ROS), 23 and that release was sustained over a period of at least 24 hours. H 2 O 2 is produced on dilution of the honey 24 by the action of glucose oxidase, 25 and reaches maximum levels when the honey is diluted to between 50 and 30% w/v. 26 Sustained ROS activity in SH1 has been demonstrated in vitro for over 3 days through the use of peroxide testing strips.
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Of note, MH is a non-peroxide honey and H 2 O 2 has been shown to be absent. 27 This may explain the differences in potency between the three honeys. SH1 represents a highly effective and promising topical antibacterial as evidenced by both in vitro experiments, and in vivo. 12, 14 A Cochrane review 2 into 'honey as a topical treatment for wounds' concluded that there is high-quality evidence that honey accelerates the healing of partial-thickness burn wounds compared with conventional dressings, and is also more effective than antiseptic for treating infected surgical wounds. The evidence for the clinical benefits of honey for wound healing, however, was equivocal, although SH1 was not available for inclusion in the referenced studies. These data presented in this and other studies 9,12,13 strongly support the use of SH1 as an antibacterial, and suggest further clinical evaluation is warranted. A rigorously controlled clinical trial is currently being planned at our centre to investigate the clinical use of SH1 further.
Limitations
However, there are limitations that must be considered. For example, the in vitro experiments all involved single species of bacteria, which have been artificially grown in the presence of the required nutrients. Biofilms in the clinical setting are likely to be vastly different in terms of their composition (for example they are likely to be composed of multiple bacterial species) and physiology (in terms of metabolic rate and presence of nutrients). Our data have shown that SH1 can prevent biofilm formation in vitro but not the impact it has on established biofilms. Preliminary work we have performed, has shown that SH1 can reduce the seeding (the release of planktonic bacterial cells from the biofilm surface so that new sites can be colonised) of pre-formed biofilms of the same panel of 16 isolates, after 24-hour exposures. Therefore, some evidence exists that honey can disrupt biofilms in vitro (Halstead et al. unpublished) , however comparable in vivo activity against biofilms remains to be tested.
The in vitro data from this study also highlights that for some isolates (PS_1054, PS_1586, PS_6749, EC_042 and MSSA_10788) the test honey may actually enhance growth at certain dilutions. For these six isolates, all honeys were equally likely to enhance biofilm growth with this typically occuring at values lower than the MBIC (1:24 for the Pseudomonas isolates, 1:96 for MSSA_10788, and 1:192 for EC_042). This may prove problematic in the clinical setting if the honey is applied at an effective concentration but is then diluted down to subinhibitory concentrations by wound exudates, or other secretions from the wound surface. An additional limitation is that the majority of clinical reports to date are anecdotal reports of patients with chronic wounds recovering after application of SH1-it would need to be demonstrated that this was due to the SH1 and not simply because the wound was already healing.
Conclusions
The work presented here supports previous in vitro findings and is consistent with the anecdotal clinical evidence. All the honeys tested, SH1, MH and Med, demonstrated antibacterial activity against the formation of biofilms. However, SH1, appears to be the most potent against a range of Grampositive and Gram-negative bacteria, including MDR organisms.
Although further randomised controlled trials are required, SH1 clearly has considerable therapeutic and infection-prevention potential for the management and treatment of chronically colonised and infected wounds, and may help to reduce the use of antibiotics and selection pressure while promoting wound healing and infection prevention.
